New biomarker could reveal Alzheimer's disease years before onset

August 14, 2013, Chempetitive Group

A study published today reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD). The results suggest that this novel potential biomarker is present in cerebral spinal fluid (CSF) at least a decade before signs of dementia manifest.

"If our initial findings can be replicated by other laboratories, the results will change the way we currently think about the causes of Alzheimer's disease," said Dr. Ramon Trullas, research professor at the CSIC Institute of Biomedical Research of Barcelona and lead author of the study that was published in Annals of Neurology. "This discovery may enable us to search for more effective treatments that can be administered during the preclinical stage."

Difficult Diagnosis

Alzheimer's disease affects more than five million Americans and is the sixth leading cause of death in the United States. At present, the only way to accurately diagnose the disease is by post-mortem neuropathological analysis. The relationship of currently known biomarkers with the cause of the disease is unclear, making it nearly impossible to diagnose preclinical stages of the disease with any real certainty.

The CSIC researchers demonstrated that a decrease in the content of mitochondrial DNA (mtDNA) in CSF may be a preclinical indicator for Alzheimer's disease; furthermore, there may be a directly causative relationship. The hypothesis is that decreased mtDNA levels in CSF reflect the diminished ability of to power the brain's , triggering their death. The decrease in the concentration of mtDNA precedes the appearance of well-known biochemical Alzheimer's biomarkers (the A?1-42, t-tau, and p-), suggesting that the pathophysiological process of Alzheimer's disease starts earlier than previously thought and that mtDNA depletion may be one of the earliest predictors for the disease.

In addition to enabling an investigation of the potential of mtDNA and Alzheimer's progression, the use of mtDNA as an index of preclinical Alzheimer's disease provides an important advantage over previous biochemical markers: the detection of this novel nucleic acid is unhampered by the technical difficulties associated with protein detection. mtDNA can be readily quantified by real-time quantitative PCR (qPCR) or droplet digital PCR (ddPCR).

Quantitation of mtDNA

Prior to this study, researchers had not reported that circulating cell-free mtDNA could be detected in human CSF. But with this study, Dr. Trullas' team was able to both detect and reproducibly quantitate mtDNA using qPCR, carefully optimized by adhering to the MIQE guidelines.

To validate their qPCR findings, Dr. Trullas' team used Bio-Rad Laboratories' QX100™ Droplet Digital™ PCR system. Unlike qPCR assays, the QX100 system provides an absolute quantification of target DNA molecules without the need for a standard curve. In addition, an important factor for their CSF analysis was that the Droplet Digital PCR system did not require sample purification to remove PCR inhibitors, as is necessary for qPCR assays.

"Droplet Digital PCR allowed us to validate our initial qPCR measurements because it provides absolute quantitation at the single-molecule level without relying on a standard curve," said Dr. Trullas. "As the technology becomes more widely adopted, we anticipate that Droplet Digital PCR will be the future of detecting mtDNA in ."

Dr. Trullas hopes that other laboratories and hospitals will successfully replicate his group's research results, confirming that reduced mtDNA levels should be investigated as a possible cause of Alzheimer's disease. By finding a way to block this degeneration, clinicians may be able to diagnose and treat Alzheimer's disease before symptoms appear.

Explore further: Rare mitochondrial mutations—maybe not so rare?

Related Stories

Rare mitochondrial mutations—maybe not so rare?

June 8, 2013
French scientists have discovered that supposedly rare mutations in the mitochondria, the 'power plants' of human cells responsible for creating energy, account for more than 7% of patients with a mitochondrial disease manifesting ...

Mechanism that allows bacteria to infect plants may inspire cure for eye disease

August 4, 2013
By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria—the energy factories within cells. Doctors might someday use the approach to treat ...

Stopping Alzheimer's before first symptoms appear

August 13, 2013
New research just out in the journal Science Translational Medicine opens the door for the development of treatments capable of stopping Alzheimer's disease (AD) before its first symptoms, that is to say before any crucial ...

Study examines immunotherapy and cerebrospinal fluid biomarkers in patients with Alzheimer's disease

April 2, 2012
Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process, ...

New approach could lead to blood test to diagnose Alzheimer's in earliest stage

May 29, 2013
Blood offers promise as a way to detect Alzheimer's disease at its earliest onset, Mayo Clinic researchers say. They envision a test that would detect distinct metabolic signatures in blood plasma that are synonymous with ...

Five CSF markers differentiate dementia, parkinsonism

August 28, 2012
(HealthDay)—Levels of five different cerebrospinal fluid (CSF) biomarkers are able to improve differentiation between common dementia and parkinsonian disorders, according to a study published online Aug. 27 in the Archives ...

Recommended for you

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.